STOCKHOLM, Dec. 11, 2023 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)
("Calliditas") today announced that it has received a Notice of
Allowance from the United States Patent and Trademark Office
(USPTO) for patent application no. 18/100,396 entitled "New
Pharmaceutical Compositions." This Notice of Allowance is
expected to result in the issuance of a U.S. patent once
administrative processes are completed.
The allowed claims cover a method of treating IgA nephropathy
with a composition that encompasses TARPEYO® (budesonide) delayed
release capsules, developed under the name
"NEFECON®". Calliditas expects the resulting patent will be
Orange Book-listable, with an anticipated expiration date in
2043. The patent, when issued, will be Calliditas' second
patent for TARPEYO in the United States.
Calliditas intends to file corresponding patent applications in
additional territories around the world, including Europe and China.
"When issued, our new patent will significantly strengthen
TARPEYO's intellectual property protection, further improving its
unique value proposition, and providing a basis for an active
program of extending patent protection of the NEFECON® franchise
globally," said CEO Renée Aguiar-Lucander.
CONTACT:
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information in the press release is information that
Calliditas is obliged to make public pursuant to the EU Market
Abuse Regulation. The information was sent for publication, through
the agency of the contact persons set out above, on December 11, 2023 at 15:15
p.m. CET.
The following files are available for download:
https://mb.cision.com/Main/16574/3891581/2485500.pdf
|
Patent Press Release
Eng
|
View original
content:https://www.prnewswire.co.uk/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-tarpeyo-302011470.html